1Dannhardt G, Kiefer W. Cyclooxygenase inhibitors--cur-rent status and furore prospects[J]. Bur J Med Chem, 2001,36(2): 109-126.
2Kneen G, Jackson W P, Islip P J, et al. Preperation of aryl-hydroxamic acid derivative compositions Containing them,and their use in medicine and other applications[P]. EP:196184,1986-10-01.
3Belley M, Gauthier M, Black C, et al. Preparation of me-thylsulfonylphenyl- 2-(5H)-furanones as COX-2 inhibitars [P]. US:6020343, 2000-02-01.
4Chan C C, Boyce S, Brideau C, et al. Rofecoxib [Vioxx,MK-0966; 4- (4'-Methylsulfonylphenyl)- 3-phenyl-2- (5H)-furanone]:a potent and orally active cyclooxygenase-2 in-hibitor. Pharmacological and biochemical profiles[J]. J Phar- macol Ezp Tber, 1999,290 (2):551-560.
5Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecox-ib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group[J]. Arch Intern Med,2000,160(12) : 1781-1787.
6Catella-Lawson F, McAdam B, Morrison B W, et al. Ef-fects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids [J]. J PharmacolExp Ther, 1999,289 (2).735-741.
7Rocha J L, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme in-hibitor rofecoxib[J]. Lancet, 2000, 357 (9272): 1946-1947.
8Laudanno O M, Cesolari J A, Esnarriaga J, et al. Gas-trointestinal damage induced by celecoxib and rofecoxib in rats[J]. Dig Dis Sci,2002,46(4) :779-784.
9Nicoll-Grfffith D A, Yergey J A, Trimbie L A, et al. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib(MK-0966, Vioxx) [J]. Bioorg Med Chem Lett, 2000, 10(23) : 2683-2686.
10Warner T D, Giullano F, Vojnovic I ,et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxy-genase-2 are associated with human gastrointestinal toxici-ty: a full in vitro analysis[J].proc Natl Acad Sci USA,1999,96(13) :7563-7568.
